Review supports imepitoin for dogs with loud-noise fear
Bottom line
Version 1
A Veterinary Evidence review concluded that imepitoin can reduce signs of fear and anxiety in dogs with loud-noise sensitivity, based on two double-blind, randomized, placebo-controlled trials in dogs exposed to fireworks or storms. The review found better owner-rated responses with imepitoin than with placebo, while also noting that adverse effects were common, especially ataxia, appetite changes, lethargy, and emesis. In the U.S., imepitoin is marketed as Pexion and is FDA-approved for treatment of noise aversion in dogs; the label recommends starting therapy two days before an expected noise event and continuing through it. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, the takeaway is that imepitoin has controlled-trial evidence behind it for predictable noise-triggered events, but the evidence base is still fairly narrow and leans heavily on pet parent-reported outcomes. The FDA approval study for fireworks-related noise aversion found 66.2% of treated dogs were rated as having a good or excellent effect, versus 25% of controls, but adverse reactions occurred more often in treated dogs, and the U.S. label says the product has not been evaluated for thunderstorm aversion. That makes case selection, counseling on expectations, and discussion of side effects especially important in general practice and behavior cases. (animaldrugsatfda.fda.gov)
What to watch: Expect continued interest in how imepitoin fits alongside behavior modification and other situational anxiolytics, especially as newer FDA-approved options for noise-related distress enter the market. (fda.gov)
Key facts
- Drug
- Imepitoin
- U.S. brand name
- Pexion
- FDA-approved use
- Treatment of noise aversion in dogs
- Approval timing
- Late 2018
- Evidence base
- Two double-blind, randomized, placebo-controlled trials
- Noise triggers studied
- Fireworks and storms
- Pivotal field study event
- New Year’s Eve fireworks
- Dose and schedule in FDA study
- 30 mg/kg orally twice daily, starting two days before the expected noise event and continuing through it
- Common adverse effects
- Ataxia, increased appetite, lethargy, and emesis
Version 2
A new Veterinary Evidence review supports imepitoin as a useful option for dogs frightened by loud noises, finding that the drug reduced owner-rated fear and anxiety signs versus placebo in two controlled clinical trials. The review centers on dogs with noise sensitivity tied to predictable triggers such as fireworks and storms, and it reinforces imepitoin’s place as an evidence-backed situational medication rather than a catch-all solution for every anxiety case. (pmc.ncbi.nlm.nih.gov)
That conclusion builds on a broader regulatory and clinical history. Imepitoin was already known in veterinary medicine as an anticonvulsant and partial agonist at the benzodiazepine-binding site of the GABA-A receptor before it was developed for canine noise aversion. In the U.S., FDA approved Pexion in late 2018 for treatment of noise aversion in dogs, and the agency’s freedom of information summary shows the pivotal field study used New Year’s Eve fireworks as the eliciting event. (pmc.ncbi.nlm.nih.gov)
The FDA summary provides the clearest numbers behind the review’s conclusion. In the effectiveness population, 59 of 89 imepitoin-treated dogs were rated by pet parents as having a good or excellent response, compared with 26 of 104 control dogs. The odds ratio for overall treatment effect was 5.048, and the treated group also had significantly lower summed noise-aversion behavior scores across fixed assessment points on New Year’s Eve and early New Year’s Day. Treatment in that study was given orally at 30 mg/kg twice daily, starting two days before the expected noise event and continuing through it. (animaldrugsatfda.fda.gov)
The review’s second key evidence source was a randomized, placebo-controlled storm-anxiety trial. That study reported that pet parents in the active-treatment group were significantly more likely to say the medication reduced fear and anxiety during storms and during other non-storm noise events. At the same time, the current U.S. label still states that Pexion has not been evaluated for aversion behaviors to thunderstorms, an important distinction between emerging literature and labeled use. (bvajournals.onlinelibrary.wiley.com)
Safety remains central to the clinical conversation. In the FDA field study, 46.5% of imepitoin-treated dogs had at least one nonserious adverse reaction, versus 12.1% of controls. The most common were ataxia, increased appetite, lethargy, and emesis, and the label also warns that drugs acting at the benzodiazepine receptor site may disinhibit fear-based behaviors and could alter aggression levels. The label further notes that safe use has not been evaluated in dogs younger than 5 months, in breeding, pregnant, or lactating dogs, or in dogs with severely impaired hepatic, renal, or cardiovascular function. (animaldrugsatfda.fda.gov)
Industry and clinical commentary has generally framed imepitoin as one tool within a multimodal plan, not a standalone fix. Continuing education and review articles for practitioners emphasize that long-term management of noise fears still relies on environmental management, counterconditioning, desensitization, and, when needed, referral to a qualified behavior professional. Reviews of current evidence also point out that two medications have been approved for canine noise aversion, underscoring that clinicians now have more than one evidence-based pharmacologic option to discuss with pet parents. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinarians, imepitoin’s value is in predictable events where advance dosing is feasible and a pet parent can monitor closely. The evidence is stronger for fireworks-related noise aversion than for thunderstorm-associated anxiety, and most outcomes in the published trials are based on pet parent observations rather than objective physiologic measures. That doesn’t diminish the practical relevance, but it does mean clinicians should set expectations carefully, weigh side-effect risk against likely benefit, and position the drug within a broader behavior plan rather than as a substitute for one. (animaldrugsatfda.fda.gov)
What to watch: The next question is where imepitoin lands in the treatment algorithm as the market evolves, particularly after FDA’s May 6, 2026 approval of Tessie, a tasipimidine oral solution indicated for both noise aversion and separation anxiety in dogs. Comparative use patterns, real-world tolerability, and whether additional labeled data emerge for storms or other triggers will likely shape how often imepitoin is chosen in first-line practice. (fda.gov)